|
|
|
| Effect of MUC1 on Biological Behaviour of Human Colorectal Cancer Cell HCT116 |
| YI Shou-hui1, WANG Dong-lin2, WU Zhi-juan2, YANG Wen-ying1, ZHAO Qi-cheng2, CHEN Xiao-pin1 |
1. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;
2. Department of Oncology, Chongqing Cancer Hospital, Chongqing 400011, China |
|
|
|
Abstract Objective: To investigate the effect of MUC1 on proliferation, invasion and chemosensitivity of human colorectal cancer cell line HCT116. Methods: The HCT116 human colon cancer cells were transfected with lentiviral vectors with and without MUC1, then selected by puromycin. The expression of MUC1 was detected by SqRT-PCR and Western blot. There were two groups in our experiment: MUC1 lentivirus group and control lentivirus group. CCK method and soft agar colony formation method were used to detect cells proliferation, Transwell membrane assay to detect cells invasion, MTT method and flow cytometry to detect cells sensitivity to oxaliplatin and the colorimetric method to detect Caspase-3 activity. Results: HCT116 cell line with stable expression of the MUC1 was acquired. Compared with control lentivirus group, the number of soft agar colonies in MUC1 lentivirus group was increased significantly (P<0.05), the number of invasive cells was increased significantly (P<0.05). Chemosensitivity was decreased in the MUC1 lentivirus group(P<0.05). Caspase-3 activity was significantly low in the MUC1 lentivirus group(P<0.05). Conclusion: MUC1 is related to the anchorage-independent growth, invasion and chemotherapy of colorectal cancer.
|
|
Received: 24 October 2014
Published: 25 January 2015
|
|
|
|
|
|
[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
[2] Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 2012, 62(4):220-241.
[3] Shimizu M, Yamauchi K. Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane. J Biochem, 1982, 91(2):515-524.
[4] Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med, 2014, 20(6):332-342.
[5] Kufe D W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013, 32(9):1073-1081.
[6] Tamada Y, Takeuchi H, Suzuki N, et al. Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci, 2007, 98(10):1586-1591.
[7] Li Y Q, Liu D, Chen D S, et al. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene, 2003, 22(38):6107-6110.
[8] Horm T M, Schroeder J A. MUC1 and metastatic cancer expression, function and therapeutic targeting. Cell Adhes Migr, 2013, 7(2):187-198.
[9] Horn G, Gaziel A, Wreschner D H, et al. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res, 2009, 315(8):1490-1504.
[10] Chen J S, Wang Q, Fu X H, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res, 2009, 39(2):177-186.
[11] Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-x(L) pathways in rat 3Y1 fibroblasts. J Biol Chem, 2004, 279(20):20607-20612.
[12] Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-Small cell lung cancer cells. Mol Cancer Ther, 2011, 10(5):806-816.
[13] Kim Y, Kang H, Jang S W, et al. Celastrol inhibits breast cancer cell invasion via suppression of NF-kappa B-mediated matrix metalloproteinase-9 Expression. Cell Physiol Biochem, 2011, 28(2):175-184.
[14] Ahmad R, Raina D, Trivedi V, et al. MUC1 oncoprotein activates the I kappa B kinase beta complex and constitutive NF-kappa B signalling. Nat Cell Biol, 2007, 9(12):U1419-U1146.
[15] Ren J, Agata N, Chen D S, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 2004, 5(2):163-175.
[16] Raina D, Ahmad R, Kumar S, et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. Embo J, 2006, 25(16):3774-3783.
[17] Deng M, Jing D D, Meng X J. Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. Asian Pac J Cancer Prev, 2013, 14(1):127-131.
[18] Raina D, Uchida Y, Kharbanda A, et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene, 2014, 33(26):3422-3431.
[19] Ren J, Raina D, Chen W, et al. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res, 2006, 4(11):873-883.
[20] Ahmad R, Alam M, Rajabi H, et al. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem, 2012, 287(25):20866-20875.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
